KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Vir Biotechnology (VIR) Shares Outstanding (Diluted Average) (2021 - 2025)

Vir Biotechnology's Shares Outstanding (Diluted Average) history spans 5 years, with the latest figure at $138.5 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Diluted Average) rose 1.67% to $138.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $138.5 million, a 1.67% increase, with the full-year FY2025 number at $138.5 million, up 1.67% from a year prior.
  • Shares Outstanding (Diluted Average) hit $138.5 million in Q4 2025 for Vir Biotechnology, roughly flat from $138.9 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Diluted Average) for VIR hit a ceiling of $138.9 million in Q3 2025 and a floor of $133.4 million in Q4 2021.
  • Historically, Shares Outstanding (Diluted Average) has averaged $135.7 million across 5 years, with a median of $135.0 million in 2022.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): fell 0.5% in 2023 and later rose 1.76% in 2024.
  • Tracing VIR's Shares Outstanding (Diluted Average) over 5 years: stood at $133.4 million in 2021, then grew by 1.03% to $134.8 million in 2022, then fell by 0.5% to $134.1 million in 2023, then grew by 1.58% to $136.2 million in 2024, then increased by 1.67% to $138.5 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for VIR at $138.5 million in Q4 2025, $138.9 million in Q3 2025, and $138.0 million in Q2 2025.